Spark Impact

Diagnostic Healthcare Ltd is a diagnostic imaging company based in Altrincham, UK, led by managing director Liat Karni and chairman Michael Ringart. The company specializes in providing a range of medical diagnostic imaging services for both public and private clients. Its offerings include MRI scans, obstetric ultrasounds, bone density scans (DEXA), cardiac testing, and comprehensive health screening and reporting services. Diagnostic Healthcare operates through a network of established centers and mobile units throughout the UK, delivering integrated solutions either at hospital sites, GP surgeries, or dedicated community locations.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Renephra Ltd., established in 2009 and headquartered in Manchester, UK, is a medical device company specializing in controlled fluid removal from the skin. Its core product employs Transdermal Fluid Removal (TFR) technology, combining micro-needles with negative pressure therapy to enable minimally invasive extraction of excess interstitial fluid. Renephra targets fluid overload and chronic oedema/lymphoedema in vascular, oncology, and other disease areas, addressing significant unmet clinical needs in an estimated £1 billion global market.

Ai2 Ltd is a biotechnology company based in Manchester, United Kingdom, established in 2004. The company specializes in the development of anti-infective peptide technology derived from the amino acid sequence of human protein Apo lipoprotein E. These peptides demonstrate broad-spectrum efficacy against various pathogens, including Gram-positive and Gram-negative bacteria, fungi, and viruses, including resistant strains. Ai2's technology has diverse applications in healthcare and personal care, encompassing ophthalmic products, oral care, advanced wound care, and medical devices. The company produces coated hydrogels, artificial joints, endotracheal tubes, wound dressings, and urinary and vascular catheters designed to prevent microbial colonization and contamination. Ai2 serves healthcare companies primarily in the United States and Europe, enabling medical practitioners to utilize its innovative technology across multiple applications.